Clinical trial
Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy
NCT00463203 is registered in ClinicalTrials.gov with Rigshospitalet, Denmark as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy
- Lead sponsor
- Rigshospitalet, Denmark
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 31, 2007
- Completion date
- June 30, 2011
- Enrollment
- 54 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.